These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29956192)

  • 21. Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging.
    Gong Z; Tas E; Yakar S; Muzumdar R
    Mol Cell Endocrinol; 2017 Nov; 455():115-130. PubMed ID: 28017785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of epicardial fat volume and nonalcoholic fatty liver disease with metabolic syndrome: From the CAESAR study.
    Kim BJ; Kim HS; Kang JG; Kim BS; Kang JH
    J Clin Lipidol; 2016; 10(6):1423-1430.e1. PubMed ID: 27919360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
    Simon TG; Corey KE; Chung RT; Giugliano R
    Dig Dis Sci; 2016 Dec; 61(12):3425-3435. PubMed ID: 27714510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parental metabolic syndrome epigenetically reprograms offspring hepatic lipid metabolism in mice.
    De Jesus DF; Orime K; Kaminska D; Kimura T; Basile G; Wang CH; Haertle L; Riemens R; Brown NK; Hu J; Männistö V; Silva AM; Dirice E; Tseng YH; Haaf T; Pihlajamäki J; Kulkarni RN
    J Clin Invest; 2020 May; 130(5):2391-2407. PubMed ID: 32250344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From "two hit theory" to "multiple hit model".
    Fang YL; Chen H; Wang CL; Liang L
    World J Gastroenterol; 2018 Jul; 24(27):2974-2983. PubMed ID: 30038464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Animal Models of Nonalcoholic Fatty Liver Disease-A Starter's Guide.
    Van Herck MA; Vonghia L; Francque SM
    Nutrients; 2017 Sep; 9(10):. PubMed ID: 28953222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?
    Targher G; Rossini M; Lonardo A
    Endocrine; 2016 Feb; 51(2):211-21. PubMed ID: 26024975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prevalence of nonalcoholic fatty liver disease and metabolic abnormalities in 387 obese children and adolescents in Beijing, China].
    Zhou X; Hou DQ; Duan JL; Sun Y; Cheng H; Zhao XY; Liu JT; Yang P; Shan XY; Mi J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2013 May; 34(5):446-50. PubMed ID: 24016432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maternal obesity increases the risk of metabolic disease and impacts renal health in offspring.
    Glastras SJ; Chen H; Pollock CA; Saad S
    Biosci Rep; 2018 Apr; 38(2):. PubMed ID: 29483369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease.
    Arias-Loste MT; Fábrega E; López-Hoyos M; Crespo J
    Biomed Res Int; 2015; 2015():319745. PubMed ID: 26491664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
    Zhao L; Cang Z; Sun H; Nie X; Wang N; Lu Y
    BMC Endocr Disord; 2017 Feb; 17(1):13. PubMed ID: 28241817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Dendritic Cells in Fibrosis Progression in Nonalcoholic Fatty Liver Disease.
    Almeda-Valdes P; Aguilar Olivos NE; Barranco-Fragoso B; Uribe M; Méndez-Sánchez N
    Biomed Res Int; 2015; 2015():768071. PubMed ID: 26339640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonobese Fatty Liver Disease.
    Kim D; Kim WR
    Clin Gastroenterol Hepatol; 2017 Apr; 15(4):474-485. PubMed ID: 27581063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endocrine Disruptors and Developmental Origins of Nonalcoholic Fatty Liver Disease.
    Treviño LS; Katz TA
    Endocrinology; 2018 Jan; 159(1):20-31. PubMed ID: 29126168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels.
    Akyuz U; Yesil A; Yilmaz Y
    Scand J Gastroenterol; 2015 Mar; 50(3):341-6. PubMed ID: 25540973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome.
    Aguilar-Olivos NE; Almeda-Valdes P; Aguilar-Salinas CA; Uribe M; Méndez-Sánchez N
    Metabolism; 2016 Aug; 65(8):1196-207. PubMed ID: 26435078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonalcoholic fatty liver disease in Asia: emerging perspectives.
    Seto WK; Yuen MF
    J Gastroenterol; 2017 Feb; 52(2):164-174. PubMed ID: 27637587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developmental origins of nonalcoholic fatty liver disease as a risk factor for exaggerated metabolic and cardiovascular-renal disease.
    Spradley FT; Smith JA; Alexander BT; Anderson CD
    Am J Physiol Endocrinol Metab; 2018 Nov; 315(5):E795-E814. PubMed ID: 29509436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.